These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [What should follow a treatment for pruritus in thrombocytosis?]. Wollina U Dtsch Med Wochenschr; 2003 Mar; 128(12):631. PubMed ID: 12649803 [No Abstract] [Full Text] [Related]
4. New approaches to the treatment of thrombocytosis. Fruchtman S Clin Adv Hematol Oncol; 2003 Feb; 1(2):92-3. PubMed ID: 16224383 [No Abstract] [Full Text] [Related]
5. A case of hydroxyurea-induced transverse melanonychia. Teo RY; Tan E Int J Dermatol; 2006 Nov; 45(11):1329-30. PubMed ID: 17076717 [No Abstract] [Full Text] [Related]
6. Hydroxyurea in essential thrombocytosis. Van Genderen PJ; Michiels JJ N Engl J Med; 1995 Sep; 333(12):802-3. PubMed ID: 7643898 [No Abstract] [Full Text] [Related]
7. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. Cortelazzo S; Finazzi G; Ruggeri M; Vestri O; Galli M; Rodeghiero F; Barbui T N Engl J Med; 1995 Apr; 332(17):1132-6. PubMed ID: 7700286 [TBL] [Abstract][Full Text] [Related]
8. Early cutaneous lesions secondary to hydroxyurea therapy. Radaelli F; Calori R; Faccini P; Maiolo AT Am J Hematol; 1998 May; 58(1):82-3. PubMed ID: 9590156 [TBL] [Abstract][Full Text] [Related]
9. A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Dingli D; Tefferi A Leuk Lymphoma; 2005 May; 46(5):641-50. PubMed ID: 16019501 [TBL] [Abstract][Full Text] [Related]
10. [A new etiology of inflammatory livedo: thrombocytosis]. Lèques B; Texier L; Verdaguer S; Hoffman-Martinot R; Paulet C; Moine M Presse Med (1893); 1969 Jan; 77(3):91-2. PubMed ID: 4389318 [No Abstract] [Full Text] [Related]
11. Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis. Karanth SS; Gupta A; Prabhu M Singapore Med J; 2014 Jan; 55(1):e7-8. PubMed ID: 24452985 [TBL] [Abstract][Full Text] [Related]
12. Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Randi ML; Ruzzon E; Tezza F; Luzzatto G; Fabris F Platelets; 2005; 16(3-4):181-4. PubMed ID: 16011962 [TBL] [Abstract][Full Text] [Related]
13. Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient. Jensen AW; Tefferi A; Arndt CA J Pediatr Hematol Oncol; 2007 Mar; 29(3):156-9. PubMed ID: 17356393 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Martínez-Trillos A; Gaya A; Maffioli M; Arellano-Rodrigo E; Calvo X; Díaz-Beyá M; Cervantes F Ann Hematol; 2010 Dec; 89(12):1233-7. PubMed ID: 20567824 [TBL] [Abstract][Full Text] [Related]